SCHEMBL2170217

SCHEMBL2170217

CN1CCC(Nc2cc(NS(=O)(=O)c3ccc(F)cc3)ccc2F)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.49
TP53 P04637 2/20 0.49
PKM P14618 1/20 0.49
HTR6 P50406 3/20 0.48
DRD2 P14416 2/20 0.48
HTR2A P28223 2/20 0.48
HTR2C P28335 2/20 0.48
DRD3 P35462 2/20 0.48
CYP3A4 P08684 3/20 0.47
LMNA P02545 3/20 0.46
KMT2A Q03164 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP2D6 P10635 2/20 0.46
POLB P06746 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 2/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6117477 0.91 TP53 (0.47) SMN1; SMN2TP53PKMHTR6CYP3A4
SCHEMBL2169741 0.90 HSD17B3 (0.49) SMN1; SMN2TP53PKMHTR6DRD2
SCHEMBL2170321 0.88 CYP3A4 (0.59) SMN1; SMN2HTR6DRD2HTR2AHTR2C
SCHEMBL2170110 0.85 L3MBTL1 (0.52) SMN1; SMN2TP53PKMHTR6HTR2A
SCHEMBL2172090 0.81 POLB (0.53) SMN1; SMN2TP53CYP3A4LMNAKMT2A
SCHEMBL2303191 0.81 HTR6 (0.50) SMN1; SMN2TP53PKMHTR6DRD2
SCHEMBL2169909 0.81 CYP3A4 (0.54) SMN1; SMN2TP53HTR6DRD2HTR2A
SCHEMBL2183002 0.80 CYP3A4 (0.49) SMN1; SMN2HTR6DRD2HTR2AHTR2C
SCHEMBL2170725 0.79 CYP3A4 (0.50) SMN1; SMN2TP53HTR6CYP3A4LMNA
SCHEMBL2170411 0.79 CYP3A4 (0.58) SMN1; SMN2HTR6DRD2HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP claimed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US claimed
EP-2346847-B1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LTD (IN) 2013-05-15 EP disclosed
US-8404720-B2 Aryl sulfonamide amine compounds and their use as 5-HT6 ligands SUVEN LIFE SCIENCES LIMITED (IN) 2013-03-26 US disclosed
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2012-05-24 US disclosed
EP-2346847-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS Suven Life Sciences Limited (IN) 2011-07-27 EP disclosed
WO-2010032258-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129816-A1 ARYL SULFONAMIDE AMINE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS HTR6, HTR1A, HTR5A SMN1; SMN2 822/4885TP53 4241/4885PKM 993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.